Departments of Surgery and *Physiology, The Medical School, The University, Newcastle upon Tyne, NE1 7RU
(Received 12 September 1974)
CB 154 lowers plasma prolactin levels in animals (Flückiger, 1972) and in man (Lutterbeck, Pryor, Vangor & Wenner, 1971), in which it has been successfully used to treat galactorrhoea (Besser, Parke, Edwards, Forsyth, & McNeilly, 1972) and to suppress puerperal lactation (Varga, Lutterbeck, Pryor, Wenner, & Erb, 1972). Hyperprolactinaemia occurs in a number of clinical disorders (Horrobin, 1974) and CB 154 may also be used in these conditions. However, the metabolic effects of this potentially useful drug have not been fully investigated in man or in animals.
Twenty male Wistar rats weighing 140–160 g were used. Ten were given 1 mg CB 154 (Sandoz batch No. 193 H3) intraperitoneally at 12.00 h the day preceding the experiment, and a second injection of 1 mg was given at 08.30 h on the
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
Sept 2018 onwards | Past Year | Past 30 Days | |
---|---|---|---|
Full Text Views | 0 | 0 | 0 |
PDF Downloads | 3 | 1 | 0 |